UnitedHealth (UNH) Current Situation
Guidance reaffirmed: Management reiterated ≥ $16.00 EPS and $445.5B–$448B revenue for FY2025. This is broadly in line with Wall Street’s expectations, signalling stability.
Market reaction: Shares broke through the $320 resistance level, which had been a ceiling for months. Technical traders view this as a bullish breakout.
Valuation context: At ~$320, UNH trades around 20x forward earnings—not cheap, but reasonable for a defensive healthcare leader with consistent growth.
---
Short-Term View
Breakout risk: After a strong run, stocks often pause or consolidate as early buyers take profits.
Catalysts ahead: Medicare Advantage enrolments, medical cost trends, and regulatory headlines can drive near-term swings.
Technical momentum: As long as UNH holds above ~$320, momentum traders will likely keep buying dips. If it falls back below that level, a near-term top could be in place.
---
Long-Term View
Business moat: UNH is the largest U.S. health insurer, with strong diversification (Optum health services, pharmacy benefit management, data analytics).
Secular drivers: Aging U.S. population, demand for cost-efficient care, and increasing penetration of value-based healthcare support steady growth.
Buffett angle: Berkshire Hathaway holds significant healthcare exposure (though more in pharma and insurance broadly). UNH is often mentioned as a Buffett-style stock—scale, predictable earnings, strong cash flow—even if Berkshire hasn’t disclosed a direct stake.
---
✅ Verdict
Short term: UNH may be approaching a local peak after the breakout—some profit-taking is likely.
Long term: The reaffirmed guidance, defensive nature, and secular tailwinds argue for continued strength. If you are a long-term investor, dips toward support levels (~$310–$315) could be attractive entries rather than exits.
Comments